Humacyte Inc. 13D/A Filing Update

TL;DR

Humacyte 13D/A updated by Niklason & Dougan's Ayabudge LLC on 3/8/24.

AI Summary

Laura E. Niklason and Brady W. Dougan, through Ayabudge LLC, have amended their Schedule 13D filing concerning Humacyte, Inc. The amendment, filed on March 8, 2024, indicates a change in the date as of which the information is reported to March 8, 2024. No specific changes in beneficial ownership percentages or dollar amounts are detailed in this excerpt.

Why It Matters

This filing update signals ongoing activity or changes in significant stakeholder positions in Humacyte, Inc., which could influence investor perception and stock movement.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant stake-building or changes in control, which can introduce volatility.

Key Players & Entities

• Humacyte, Inc. (company) — Subject company
• Laura E. Niklason (person) — Filing person
• Brady W. Dougan (person) — Filing person
• Ayabudge LLC (company) — Filing entity
• Alpha Healthcare Acquisition Corp. (company) — Former company name

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• humaschedule13d_a6.htm (SC 13D/A) — 112KB
• 0001818382-24-000029.txt ( ) — 113KB

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer

of the Schedule 13D is hereby amended and restated in full as follows

Item 5 of the Schedule 13D is hereby amended and restated in full as follows (a)-(b) Number of shares of Common Stock beneficially owned Laura E. Niklason, M.D., Ph.D. 10,153,195 shares Brady W. Dougan 10,153,195 shares Ayabudge LLC 6,191,140 shares Percent of class Laura E. Niklason, M.D., Ph.D. 8.4% Brady W. Dougan 8.4% Ayabudge LLC 5.2% The percentage ownership was calculated based upon 118,985,256 shares of the Issuer's Common Stock outstanding, which includes 103,575,256 shares of the Issuer's Common Stock outstanding as of November 2, 2023, as reported in the Form 10-Q filed with the SEC on November 9, 2023 and 15,410,000 shares issued on March 5, 2024 in the Equity Offering as reported in the Prospectus Supplement filed with the SEC on March 1, 2024. This Amendment No. 6 is being filed to report a decrease of more than one percent in the percentage of outstanding shares of Common Stock that the Reporting Persons beneficially own, which resulted solely from the increase in the number of shares of Common Stock outstanding following the Equity Offering. CUSIP No. 44486Q 103 Page 6 of 7 Pages Number of shares as to which such person has (i) Sole power to vote or to direct the vote Laura E. Niklason, M.D., Ph.D. 0 shares Brady W. Dougan 0 shares Ayabudge LLC 0 shares (ii) Shared power to vote or to direct the vote Laura E. Niklason, M.D., Ph.D. 10,153,195 shares Brady W. Dougan 10,153,195 shares Ayabudge LLC 6,191,140 shares (iii) Sole power to dispose or to direct the disposition of Laura E. Niklason, M.D., Ph.D. 0 shares Brady W. Dougan 0 shares Ayabudge LLC 0 shares (iv) Shared power to dispose or to direct the disposition of Laura E. Niklason, M.D., Ph.D. 10,153,195 shares Brady W. Dougan 10,153,195 shares Ayabudge LLC 6,191,140 shares (c) Except as reported in this Schedule 13D, none of the Reporting Persons has effected any transactions in the Common Stock during the past sixty (60) days. (d) Not applic

View Full Filing

View this SC 13D/A filing on SEC EDGAR